[email protected] +44 20 8123 2220 (UK) +1 732 587 5005 (US) Contact Us | FAQ |

Global Non-Invasive Prenatal Testing (NIPT) Market: Focus on Tests, Methods, Platforms, Applications, 26 Countries’ Analysis, Patent Landscape, and Competitive Landscape - Analysis and Forecast, 2018-2028

October 2018 | 406 pages | ID: G9ADEEFD560EEN
BIS Research Inc.

US$ 4,500.00 US$ 5,000.00 -10 %
Offer valid until March 31, 2024!

E-mail Delivery (PDF)

Download PDF Leaflet

Accepted cards
Wire Transfer
Checkout Later
Need Help? Ask a Question
Hard copy option is available on any of the options above at an additional charge of $500. Please email us at [email protected] with your request.

The life science industry is focused on the development of advanced NIPT tests using genome sequencing technologies for the early detection of genetic disorders. The increasing prevalence of genetic disorders and development of the healthcare infrastructure are promoting the adoption of the NIPT for better diagnosis and improved prenatal care.

Non-invasive prenatal testing (NIPT) is a sophisticated method used for the screening of chromosomal abnormalities developing in the fetus. Currently, NIPT is considered as a valuable test for the pregnant women to provide cost-effective and highly efficient early diagnosis of genetic disorders. Moreover, advancements in genome sequencing technologies reduce turnaround time and the complexity of diagnosis with next generation sequencing (NGS). The NGS technology provides several opportunities to develop the non-invasive diagnostic procedures for an early and accurate detection of various genetic disorders. The life science industry is witnessing significant growth of NIPT tests developed using the NGS technology. Several biotechnology companies are now indulging in the research and development of such NGS-based NIPT products. Furthermore, the advent of genome sequencing technologies in the life science industry has enabled the companies to detect the genetic diseases at an early stage and provide accurate results to remain competitive in the market.

The purpose of this study is to gain a holistic view of the NIPT market in terms of various influencing factors, such as recent trends, regulatory requirements, and technological advancements of the market. The scope of this report constitutes a detailed study of the tests associated with the global NIPT market across different regions. The market has been segmented into ‘tests,’ ‘methods,’ ‘platforms,’ ‘applications,’ and ‘regions.’ The report presents the reader with an opportunity to unlock comprehensive insights with respect to the market and helps in forming well-informed strategic decisions. The research uncovers some of the substantial parameters that must be taken into consideration before entering the market.

This research report aims at answering various aspects of the global NIPT market with the help of the key factors driving the market, restraints, and challenges that can inhibit the overall market growth and the current growth opportunities that are going to shape the future trajectory of the market expansion. The report includes an in-depth examination of the key players and recent developments taking place in this market. Moreover, the report includes chapters on market dynamics (market drivers, opportunities, and challenges) and industry analysis as well.

The research study highlights the factors governing the industry attractiveness with Porter’s Five Forces for a comprehensive understanding of the global NIPT market. Moreover, the study includes detailed product mapping with further sub-segmentation in various countries, and in each sub-segment, the key market trends, list of the key companies, and the key strategies and developments have also been discussed.

The answers to the following key questions can be derived from this report:
  • How did the NIPT market evolve, and what is its scope in the future?
  • What are the major market drivers, challenges, and opportunities in the global NIPT market?
  • What are the key developmental strategies that are implemented by the key players to sustain in this market?
  • How the influencing factors will affect the industry attractiveness?
  • How NIPT is utilized for the detection of chromosomal abnormalities?
  • How investments by public and private companies and government organizations will affect the global NIPT market?
  • What was the market size of the leading segments and sub-segments of the global NIPT market in 2017?
  • How will the industry evolve during the forecast period 2018-2028?
  • What will be the growth rate of the NIPT during the forecast period?
  • How will each segment of the global NIPT market grow during the forecast period, and what will be the revenue generated by each of the segments by the end of 2028?
  • Which test segment, and application segment is expected to register the highest CAGR for the NIPT market?
  • What is the market size of NIPT in different countries of the world?
  • Which geographical region will contribute to the highest sales of NIPT?
  • Who are the key players in the NIPT market, and what are their contributions?
The key players who have been contributing significantly to the NIPT market include Agilent Technologies, Inc., Annoroad Gene Technology, Berry Genomics Co., Ltd., BGI Diagnosis, Centogene AG, Counsyl, Inc., Eurofins Scientific, F. Hoffmann-La Roche AG, Illumina, Inc., Laboratory Corporation of America Holdings, Natera, Inc., Next Biosciences, NIPD Genetics, PerkinElmer, Inc., Premaitha Health Plc, and Quest Diagnostics Incorporated, among others.
EXECUTIVE SUMMARY

1 MARKET OVERVIEW

1.1 Introduction
1.2 NIPT Approach
1.3 Different Methods of NIPT
1.4 Benefits and Risks Associated with NIPT
1.5 Technological Advancements
1.6 World Economic Outlook of Prenatal Testing Market, 2017
1.7 Global NIPT Market Scenario
1.8 Assumptions and Limitations for Market Size Calculations

2 MARKET DYNAMICS

2.1 Overview
2.2 Impact Analysis
2.3 Market Drivers
2.4 Market Restraints
2.5 Market Opportunities

3 COMPETITIVE LANDSCAPE

3.1 Introduction
3.2 Key Developments and Strategies
  3.2.1 Product Launches and Enhancements
  3.2.2 Joint Ventures, Partnerships, and Collaborations
  3.2.3 Mergers and Acquisitions
  3.2.4 Business Expansions, Awards, Recognitions, Certifications, and Others
3.3 Market Share Analysis
3.4 Growth Share Matrix (by Test), 2017
3.5 Growth Share Matrix (by Region), 2017
3.6 Key Stakeholders of NIPT Market
3.7 Industry Attractiveness
  3.7.1 Bargaining Power of Suppliers
  3.7.2 Bargaining Power of Buyers
  3.7.3 Threat of New Entrants
  3.7.4 Threat of Substitute Products
  3.7.5 Intensity of Competitive Rivalry

4 INDUSTRY INSIGHTS

4.1 Introduction
4.2 Patent Analysis
4.3 Clinical Laboratory Improvement Amendments (CLIA) Program
4.4 List of Regulatory Bodies

5 GLOBAL NON-INVASIVE PRENATAL TESTING (NIPT) MARKET (BY TEST)

5.1 Overview
5.2 Verifi
5.3 MaterniT21 PLUS and MaterniT GENOME
5.4 PrenaTest, GeneSafe, and PrenatalSAFE
5.5 Panorama
5.6 QNatal Advanced
5.7 Harmony
5.8 IONA
5.9 NIFTY
5.10 Bambni
5.11 Others

6 GLOBAL NON-INVASIVE PRENATAL TESTING (NIPT) MARKET (BY METHOD)

6.1 Overview
6.2 cf-DNA
6.3 FCMB

7 GLOBAL NON-INVASIVE PRENATAL TESTING (NIPT) MARKET (BY PLATFORM)

7.1 Overview
7.2 NGS
7.3 MPSS
7.4 Others

8 GLOBAL NON-INVASIVE PRENATAL TESTING (NIPT) MARKET (BY APPLICATION)

8.1 Overview
8.2 Trisomy Detection
8.3 Microdeletion Detection
8.4 Others

9 GLOBAL NON-INVASIVE PRENATAL TESTING (NIPT) MARKET (BY REGION)

9.1 Overview
9.2 Global Insights
9.3 North America
  9.3.1 North America Market Dynamics
  9.3.2 North America Market (by Country)
    9.3.2.1 The U.S.
    9.3.2.2 Canada
9.4 Europe
  9.4.1 Europe Market Dynamics
  9.4.2 Europe Market (by Country)
    9.4.2.1 The U.K.
    9.4.2.2 Germany
    9.4.2.3 France
    9.4.2.4 Italy
    9.4.2.5 Spain
    9.4.2.6 The Netherlands
    9.4.2.7 Belgium
    9.4.2.8 Switzerland
    9.4.2.9 Sweden
    9.4.2.10 Denmark
    9.4.2.11 Poland
    9.4.2.12 Russia
    9.4.2.13 Rest-of-Europe
9.5 Asia-Pacific
  9.5.1 Asia-Pacific Market Dynamics
  9.5.2 Asia-Pacific (by Country)
    9.5.2.1 China
    9.5.2.2 Japan
    9.5.2.3 Australia
    9.5.2.4 India
    9.5.2.5 Singapore
    9.5.2.6 Hong Kong
    9.5.2.7 Malaysia
    9.5.2.8 Indonesia
    9.5.2.9 Vietnam
    9.5.2.10 South Korea
    9.5.2.11 Philippines
    9.5.2.12 Thailand
    9.5.2.13 Rest-of-Asia-Pacific
9.6 Rest-of-the-World

10 COMPANY PROFILES

10.1 Overview
10.2 Agilent Technologies, Inc.
  10.2.1 Overview
  10.2.2 Corporate Summary
  10.2.3 Product Offerings for Global NIPT Market
  10.2.4 Financials
    10.2.4.1 Financial Summary
  10.2.5 SWOT Analysis
10.3 Annoroad Gene Technology
  10.3.1 Overview
  10.3.2 Corporate Summary
  10.3.3 Product Offerings for Global NIPT Market
  10.3.4 SWOT Analysis
10.4 Berry Genomics Co., Ltd.
  10.4.1 Overview
  10.4.2 Corporate Summary
  10.4.3 Product Offerings for Global NIPT Market
  10.4.4 SWOT Analysis
10.5 BGI Diagnosis
  10.5.1 Overview
  10.5.2 Corporate Summary
  10.5.3 Product Offerings for Global NIPT Market
  10.5.4 SWOT Analysis
10.6 Centogene AG
  10.6.1 Overview
  10.6.2 Corporate Summary
  10.6.3 Product Offerings for Global NIPT Market
  10.6.4 SWOT Analysis
10.7 Counsyl, Inc. (Subsidiary of Myriad Genetics, Inc.)
  10.7.1 Overview
10.8 Myriad Genetics, Inc.
  10.8.1 Overview
  10.8.2 Corporate Summary
  10.8.3 Product Offerings for Global NIPT Market
  10.8.4 Financials
    10.8.4.1 Financial Summary
  10.8.5 SWOT Analysis
10.9 LifeCodexx AG (Subsidiary of Eurofins Scientific)
  10.9.1 Overview
10.10 EUROFINS Genoma Group (Subsidiary of Eurofins Scientific)
  10.10.1 Overview
10.11 Eurofins Scientific
  10.11.1 Overview
  10.11.2 Corporate Summary
  10.11.3 Product Offerings for Global NIPT Market
  10.11.4 Financials
    10.11.4.1 Financial Summary
  10.11.5 SWOT Analysis
10.12 F. Hoffmann-La Roche AG
  10.12.1 Overview
  10.12.2 Corporate Summary
  10.12.3 Product Offerings for Global NIPT Market
  10.12.4 Financials
    10.12.4.1 Financial Summary
  10.12.5 SWOT Analysis
10.13 Illumina, Inc.
  10.13.1 Overview
  10.13.2 Corporate Summary
  10.13.3 Product Offerings for Global NIPT Market
  10.13.4 Financials
    10.13.4.1 Financial Summary
  10.13.5 SWOT Analysis
10.14 Natera, Inc.
  10.14.1 Overview
  10.14.2 Corporate Summary
  10.14.3 Product Offerings for Global NIPT Market
  10.14.4 Financials
    10.14.4.1 Financial Summary
  10.14.5 SWOT Analysis
10.15 Next Biosciences
  10.15.1 Overview
  10.15.2 Corporate Summary
  10.15.3 Product Offerings for Global NIPT Market
  10.15.4 SWOT Analysis
10.16 NIPD Genetics
  10.16.1 Overview
  10.16.2 Corporate Summary
  10.16.3 Product Offerings for Global NIPT Market
  10.16.4 SWOT Analysis
10.17 PerkinElmer, Inc.
  10.17.1 Overview
  10.17.2 Corporate Summary
  10.17.3 Product Offerings for Global NIPT Market
  10.17.4 Financials
    10.17.4.1 Financial Summary
  10.17.5 SWOT Analysis
10.18 Premaitha Health Plc
  10.18.1 Overview
  10.18.2 Corporate Summary
  10.18.3 Product Offerings for Global NIPT Market
  10.18.4 Financials
    10.18.4.1 Financial Summary
  10.18.5 SWOT Analysis
10.19 Quest Diagnostics Incorporated
  10.19.1 Overview
  10.19.2 Corporate Summary
  10.19.3 Product Offerings for Global NIPT Market
  10.19.4 Financials
    10.19.4.1 Financial Summary
  10.19.5 SWOT Analysis
10.20 Sequenom, Inc. (Subsidiary of Laboratory Corporation of America Holdings)
  10.20.1 Overview
10.21 Laboratory Corporation of America Holdings
  10.21.1 Overview
  10.21.2 Corporate Summary
  10.21.3 Product Offerings for Global NIPT Market
  10.21.4 Financials
    10.21.4.1 Financial Summary
  10.21.5 SWOT Analysis

11 REPORT SCOPE AND METHODOLOGY

11.1 Scope of the Report
11.2 Global NIPT Market Segmentation
11.3 Research Methodology
  11.3.1 Primary Research
  11.3.2 Secondary Research
  11.3.3 Key Data Points from Primary Sources
  11.3.4 Key Data Points from Secondary Sources
  11.3.5 Data Triangulation
  11.3.6 Top-Down Approach (Segment Wise Analysis)
  11.3.7 Bottom-Up Approach (Segmental Analysis)
11.4 Assumptions and Limitations
11.5 Data and Prediction Modelling
I Annexure 1: Recent Key Developments (2014 – 2018)
II Annexure 2: Product Mapping
III Annexure 3: Patent Landscape

LIST OF TABLES

1 GLOBAL NIPT MARKET (2017 AND 2028)

2 MAJOR CHROMOSOMAL ANEUPLOIDIES

3 INCIDENCE RATE OF MAJOR CHROMOSOMAL ANEUPLOIDIES

4 TECHNOLOGICAL APPROACH FOR NIPT

5 IMPACT ANALYSIS OF MARKET DYNAMICS

6 LIST OF REGULATORY AUTHORITIES INVOLVED IN CLIA PROGRAM

7 LIST OF REGULATORY BODIES

8 NIPT MARKET (BY TEST), 2017-2028, ($MILLION)

9 NIPT MARKET (BY TEST), 2017-2028, (UNITS)

10 NORTH AMERICA NIPT MARKET (BY TEST), 2017-2028, ($MILLION)

11 NORTH AMERICA NIPT MARKET (BY TEST), 2017-2028, (UNITS)

12 EUROPE NIPT MARKET (BY TEST), 2017-2028, ($MILLION)

13 EUROPE NIPT MARKET (BY TEST), 2017-2028, (UNITS)

14 EUROPE NIPT MARKET (BY COUNTRY), 2017-2028, ($MILLION)

15 EUROPE NIPT MARKET (BY COUNTRY), 2017-2028, (UNITS)

16 ASIA-PACIFIC NIPT MARKET (BY TEST), 2017-2028, ($MILLION)

17 ASIA-PACIFIC NIPT MARKET (BY TEST), 2017-2028, (UNITS)

18 ASIA-PACIFIC NIPT MARKET (BY COUNTRY), 2017-2028, ($MILLION)

19 ASIA-PACIFIC NIPT MARKET (BY COUNTRY), 2017-2028, (UNITS)

20 REST-OF-THE-WORLD NIPT MARKET (BY TEST), 2017-2028, ($MILLION)

21 REST-OF-THE-WORLD NIPT MARKET (BY TEST), 2017-2028, (UNITS)

LIST OF FIGURES

1 IMPACT OF MARKET DRIVERS AND MARKET RESTRAINTS

2 MARKET STATISTICS

3 GLOBAL NIPT MARKET (BY TEST), $MILLION

4 GLOBAL NIPT MARKET (BY TEST), UNITS

5 GLOBAL NIPT MARKET (BY METHOD), 2017

6 GLOBAL NIPT MARKET (BY METHOD), 2028

7 GLOBAL NIPT MARKET (BY APPLICATION), 2017

8 GLOBAL NIPT MARKET (BY APPLICATION), 2028

9 GLOBAL NIPT MARKET VALUE (BY REGION), 2017 AND 2028

10 GLOBAL NIPT MARKET VOLUME (BY REGION), 2017 AND 2028

11 GLOBAL NIPT MARKET (BY REGION), 2017

12 GLOBAL NIPT MARKET (BY REGION), 2028

13 PRENATAL TESTING TIMELINE DURING PREGNANCY

14 DIFFERENT INDICATIONS FOR NIPT

15 NIPT APPROACH

16 BENEFITS AND RISKS ASSOCIATED WITH NIPT

17 ECOSYSTEM PLAYERS OF GLOBAL PRENATAL TESTING MARKET

18 GLOBAL PRENATAL TESTING MARKET: OPPORTUNITY MATRIX

19 GLOBAL NIPT MARKET VALUE (2017-2028)

20 GLOBAL NIPT MARKET VOLUME (2017-2028)

21 COMPETITIVE LANDSCAPE (JANUARY 2014-AUGUST 2018)

22 SHARE OF KEY DEVELOPMENTS AND STRATEGIES (JANUARY 2014-AUGUST 2018)

23 PRODUCT LAUNCH SHARE, BY COMPANIES

24 JOINT VENTURES, PARTNERSHIPS, AND COLLABORATIONS SHARE, BY COMPANIES

25 MARKET SHARE ANALYSIS

26 GROWTH SHARE MATRIX (BY TEST), 2017

27 GROWTH SHARE MATRIX (BY REGION), 2017

28 PORTER’S FIVE FORCES ANALYSIS

29 INDUSTRY INSIGHTS (JANUARY 2014-AUGUST 2018)

30 PATENT SHARE (BY ASSIGNEE)

31 CLASSIFICATION OF TESTS IN CLIA PROGRAM

32 NIPT MARKET, BY TEST

33 GLOBAL NIPT MARKET (BY VERIFI), BY REVENUE, 2017-2028

34 GLOBAL NIPT MARKET (BY VERIFI), BY VOLUME, 2017-2028

35 GLOBAL NIPT MARKET (BY MATERNIT21 PLUS AND MATERNIT GENOME), BY REVENUE, 2017-2028

36 GLOBAL NIPT MARKET (BY MATERNIT21 PLUS AND MATERNIT GENOME), BY VOLUME, 2017-2028

37 GLOBAL NIPT MARKET (BY PRENATEST, GENESAFE, AND PRENATALSAFE), BY REVENUE, 2017-2028

38 GLOBAL NIPT MARKET (BY PRENATEST, GENESAFE, AND PRENATALSAFE), BY VOLUME, 2017-2028

39 GLOBAL NIPT MARKET (BY PANORAMA), BY REVENUE, 2017-2028

40 GLOBAL NIPT MARKET (BY PANORAMA), BY VOLUME, 2017-2028

41 GLOBAL NIPT MARKET (BY QNATAL ADVANCED), BY REVENUE, 2017-2028

42 GLOBAL NIPT MARKET (BY QNATAL ADVANCED), BY VOLUME, 2017-2028

43 GLOBAL NIPT MARKET (BY HARMONY), BY REVENUE, 2017-2028

44 GLOBAL NIPT MARKET (BY HARMONY), BY VOLUME, 2017-2028

45 GLOBAL NIPT MARKET (BY IONA), BY REVENUE, 2017-2028

46 GLOBAL NIPT MARKET (BY IONA), BY VOLUME, 2017-2028

47 GLOBAL NIPT MARKET (BY NIFTY), BY REVENUE, 2017-2028

48 GLOBAL NIPT MARKET (BY NIFTY), BY VOLUME, 2017-2028

49 GLOBAL NIPT MARKET (BY BAMBNI), BY REVENUE, 2017-2028

50 GLOBAL NIPT MARKET (BY BAMBNI), BY VOLUME, 2017-2028

51 GLOBAL NIPT MARKET (BY OTHERS), BY REVENUE, 2017-2028

52 GLOBAL NIPT MARKET (BY OTHERS), BY VOLUME, 2017-2028

53 GLOBAL NIPT MARKET SHARE (BY METHOD), 2017

54 GLOBAL NIPT MARKET (BY METHOD), BY REVENUE, 2017-2028

55 GLOBAL NIPT MARKET (BY METHOD), BY VOLUME, 2017-2028

56 GLOBAL NIPT MARKET (BY CF-DNA), BY REVENUE, 2017-2028

57 GLOBAL NIPT MARKET (BY CF-DNA), BY VOLUME, 2017-2028

58 GLOBAL NIPT MARKET (BY FCMB), BY REVENUE, 2017-2028

59 GLOBAL NIPT MARKET (BY FCMB), BY VOLUME, 2017-2028

60 GLOBAL NIPT MARKET SHARE (BY PLATFORM), 2017

61 GLOBAL NIPT MARKET (BY PLATFORM), BY REVENUE, 2017-2028

62 GLOBAL NIPT MARKET (BY PLATFORM), BY VOLUME, 2017-2028

63 GLOBAL NIPT MARKET (BY NGS), BY REVENUE, 2017-2028

64 GLOBAL NIPT MARKET (BY NGS), BY VOLUME, 2017-2028

65 GLOBAL NIPT MARKET (BY MPSS), BY REVENUE, 2017-2028

66 GLOBAL NIPT MARKET (BY MPSS), BY VOLUME, 2017-2028

67 GLOBAL NIPT MARKET (BY OTHERS), BY REVENUE, 2017-2028

68 GLOBAL NIPT MARKET (BY OTHERS), BY VOLUME, 2017-2028

69 GLOBAL NIPT MARKET SHARE (BY APPLICATION), 2017

70 GLOBAL NIPT MARKET (BY APPLICATION), BY REVENUE, 2017-2028

71 GLOBAL NIPT MARKET (BY APPLICATION), BY VOLUME, 2017-2028

72 GLOBAL NIPT MARKET (BY TRISOMY DETECTION), BY REVENUE, 2017-2028

73 GLOBAL NIPT MARKET (BY TRISOMY DETECTION), BY VOLUME, 2017-2028

74 GLOBAL NIPT MARKET (BY MICRODELETION DETECTION), BY REVENUE, 2017-2028

75 GLOBAL NIPT MARKET (BY MICRODELETION DETECTION), BY VOLUME, 2017-2028

76 GLOBAL NIPT MARKET (BY OTHERS), BY REVENUE, 2017-2028

77 GLOBAL NIPT MARKET (BY OTHERS), BY VOLUME, 2017-2028

78 GLOBAL NIPT MARKET (BY REGION), BY REVENUE, 2017-2028

79 GLOBAL NIPT MARKET (BY REGION), BY VOLUME, 2017-2028

80 GLOBAL NIPT MARKET SHARE, BY REGION (2017)

81 GLOBAL NIPT MARKET SHARE, BY REGION (2028)

82 NORTH AMERICA NIPT MARKET, BY REVENUE, 2017-2028

83 NORTH AMERICA NIPT MARKET, BY VOLUME, 2017-2028

84 NORTH AMERICA NIPT MARKET (BY COUNTRY), BY REVENUE, 2017-2028

85 NORTH AMERICA NIPT MARKET (BY COUNTRY), BY VOLUME, 2017-2028

86 THE U.S. NIPT MARKET, BY REVENUE, 2017-2028

87 THE U.S. NIPT MARKET, BY VOLUME, 2017-2028

88 CANADA NIPT MARKET, BY REVENUE, 2017-2028

89 CANADA NIPT MARKET, BY VOLUME, 2017-2028

90 EUROPE NIPT MARKET, BY REVENUE, 2017-2028

91 EUROPE NIPT MARKET, BY VOLUME, 2017-2028

92 THE U.K. NIPT MARKET, BY REVENUE, 2017-2028

93 THE U.K. NIPT MARKET, BY VOLUME, 2017-2028

94 GERMANY NIPT MARKET, BY REVENUE, 2017-2028

95 GERMANY NIPT MARKET, BY VOLUME, 2017-2028

96 FRANCE NIPT MARKET, BY REVENUE, 2017-2028

97 FRANCE NIPT MARKET, BY VOLUME, 2017-2028

98 ITALY NIPT MARKET, BY REVENUE, 2017-2028

99 ITALY NIPT MARKET, BY VOLUME, 2017-2028

100 SPAIN NIPT MARKET, BY REVENUE, 2017-2028

101 SPAIN NIPT MARKET, BY VOLUME, 2017-2028

102 THE NETHERLANDS NIPT MARKET, BY REVENUE, 2017-2028

103 THE NETHERLANDS NIPT MARKET, BY VOLUME, 2017-2028

104 BELGIUM NIPT MARKET, BY REVENUE, 2017-2028

105 BELGIUM NIPT MARKET, BY VOLUME, 2017-2028

106 SWITZERLAND NIPT MARKET, BY REVENUE, 2017-2028

107 SWITZERLAND NIPT MARKET, BY VOLUME, 2017-2028

108 SWEDEN NIPT MARKET, BY REVENUE, 2017-2028

109 SWEDEN NIPT MARKET, BY VOLUME, 2017-2028

110 DENMARK NIPT MARKET, BY REVENUE, 2017-2028

111 DENMARK NIPT MARKET, BY VOLUME, 2017-2028

112 POLAND NIPT MARKET, BY REVENUE, 2017-2028

113 POLAND NIPT MARKET, BY VOLUME, 2017-2028

114 RUSSIA NIPT MARKET, BY REVENUE, 2017-2028

115 RUSSIA NIPT MARKET, BY VOLUME, 2017-2028

116 REST-OF-EUROPE NIPT MARKET, BY REVENUE, 2017-2028

117 REST-OF-EUROPE NIPT MARKET, BY VOLUME, 2017-2028

118 ASIA-PACIFIC NIPT MARKET, BY REVENUE, 2017-2028

119 ASIA-PACIFIC NIPT MARKET, BY VOLUME, 2017-2028

120 CHINA NIPT MARKET, BY REVENUE, 2017-2028

121 CHINA NIPT MARKET, BY VOLUME, 2017-2028

122 JAPAN NIPT MARKET, BY REVENUE, 2017-2028

123 JAPAN NIPT MARKET, BY VOLUME, 2017-2028

124 AUSTRALIA NIPT MARKET, BY REVENUE, 2017-2028

125 AUSTRALIA NIPT MARKET, BY VOLUME, 2017-2028

126 INDIA NIPT MARKET, BY REVENUE, 2017-2028

127 INDIA NIPT MARKET, BY VOLUME, 2017-2028

128 SINGAPORE NIPT MARKET, BY REVENUE, 2017-2028

129 SINGAPORE NIPT MARKET, BY VOLUME, 2017-2028

130 HONG KONG NIPT MARKET, BY REVENUE, 2017-2028

131 HONG KONG NIPT MARKET, BY VOLUME, 2017-2028

132 MALAYSIA NIPT MARKET, BY REVENUE, 2017-2028

133 MALAYSIA NIPT MARKET, BY VOLUME, 2017-2028

134 INDONESIA NIPT MARKET, BY REVENUE, 2017-2028

135 INDONESIA NIPT MARKET, BY VOLUME, 2017-2028

136 VIETNAM NIPT MARKET, BY REVENUE, 2017-2028

137 VIETNAM NIPT MARKET, BY VOLUME, 2017-2028

138 SOUTH KOREA NIPT MARKET, BY REVENUE, 2017-2028

139 SOUTH KOREA NIPT MARKET, BY VOLUME, 2017-2028

140 PHILIPPINES NIPT MARKET, BY REVENUE, 2017-2028

141 PHILIPPINES NIPT MARKET, BY VOLUME, 2017-2028

142 THAILAND NIPT MARKET, BY REVENUE, 2017-2028

143 THAILAND NIPT MARKET, BY VOLUME, 2017-2028

144 REST-OF-ASIA-PACIFIC NIPT MARKET, BY REVENUE, 2017-2028

145 REST-OF-ASIA-PACIFIC NIPT MARKET, BY VOLUME, 2017-2028

146 REST-OF-THE-WORLD NIPT MARKET, BY REVENUE, 2017-2028

147 REST-OF-THE-WORLD NIPT MARKET, BY VOLUME, 2017-2028

148 SHARE OF KEY COMPANY PROFILES (BY COMPANY TYPE)

149 AGILENT TECHNOLOGIES, INC.: OVERALL PRODUCT PORTFOLIO

150 AGILENT TECHNOLOGIES, INC.: PRODUCT PORTFOLIO FOR GLOBAL NIPT MARKET

151 AGILENT TECHNOLOGIES, INC.: OVERALL FINANCIALS (2015-2017)

152 AGILENT TECHNOLOGIES, INC.: REVENUE BY BUSINESS SEGMENTS (2015-2017)

153 AGILENT TECHNOLOGIES, INC.: REVENUE BY REGION (2015-2017)

154 AGILENT TECHNOLOGIES, INC.: SWOT ANALYSIS

155 ANNOROAD GENE TECHNOLOGY: OVERALL PRODUCT PORTFOLIO

156 ANNOROAD GENE TECHNOLOGY: PRODUCT PORTFOLIO FOR GLOBAL NIPT MARKET

157 ANNOROAD GENE TECHNOLOGY: SWOT ANALYSIS

158 BERRY GENOMICS CO., LTD.: OVERALL PRODUCT PORTFOLIO

159 BERRY GENOMICS CO., LTD.: PRODUCT PORTFOLIO FOR GLOBAL NIPT MARKET

160 BERRY GENOMICS CO., LTD.: SWOT ANALYSIS

161 BGI DIAGNOSIS: OVERALL PRODUCT PORTFOLIO

162 BGI DIAGNOSIS: PRODUCT PORTFOLIO FOR GLOBAL NIPT MARKET

163 BGI DIAGNOSIS: SWOT ANALYSIS

164 CENTOGENE AG: OVERALL PRODUCT PORTFOLIO

165 CENTOGENE AG: PRODUCT PORTFOLIO FOR GLOBAL NIPT MARKET

166 CENTOGENE AG: SWOT ANALYSIS

167 MYRIAD GENETICS, INC.: OVERALL PRODUCT PORTFOLIO

168 MYRIAD GENETICS, INC.: PRODUCT OFFERINGS FOR GLOBAL NIPT MARKET

169 MYRIAD GENETICS, INC.: OVERALL FINANCIALS (2015-2017)

170 MYRIAD GENETICS, INC.: NET REVENUE BY BUSINESS SEGMENT (2015-2017)

171 MYRIAD GENETICS, INC.: SWOT ANALYSIS

172 EUROFINS SCIENTIFIC: OVERALL PRODUCT PORTFOLIO

173 EUROFINS SCIENTIFIC: PRODUCT OFFERINGS FOR GLOBAL NIPT MARKET

174 EUROFINS SCIENTIFIC: OVERALL FINANCIALS (2015-2017)

175 EUROFINS SCIENTIFIC: NET REVENUE BY REGION (2015-2017)

176 EUROFINS SCIENTIFIC: SWOT ANALYSIS

177 F. HOFFMANN-LA ROCHE AG: OVERALL PRODUCT PORTFOLIO

178 F. HOFFMANN-LA ROCHE AG: PRODUCT PORTFOLIO FOR GLOBAL NIPT MARKET

179 F. HOFFMANN-LA ROCHE AG: OVERALL FINANCIALS (2015-2017)

180 F. HOFFMANN-LA ROCHE AG: NET REVENUE BY BUSINESS SEGMENT (2015-2017)

181 F. HOFFMANN-LA ROCHE AG: NET REVENUE BY DIAGNOSTICS SUB-DIVISION (2015-2017)

182 F. HOFFMANN-LA ROCHE AG: NET REVENUE BY REGION (2015-2017)

183 F. HOFFMANN-LA ROCHE AG: SWOT ANALYSIS

184 ILLUMINA, INC.: OVERALL PRODUCT PORTFOLIO

185 ILLUMINA, INC.: PRODUCT OFFERINGS FOR GLOBAL NIPT MARKET

186 ILLUMINA, INC.: OVERALL FINANCIALS (2015-2017)

187 ILLUMINA, INC.: NET REVENUE BY BUSINESS SEGMENT (2015-2017)

188 ILLUMINA, INC.: NET REVENUE BY REGION (2015-2017)

189 ILLUMINA, INC.: SWOT ANALYSIS

190 NATERA, INC.: OVERALL PRODUCT PORTFOLIO

191 NATERA, INC.: PRODUCT OFFERINGS FOR GLOBAL NIPT MARKET

192 NATERA, INC.: OVERALL FINANCIALS (2015-2017)

193 NATERA, INC.: REVENUE BY REGION (2015-2017)

194 NATERA, INC.: SWOT ANALYSIS

195 NEXT BIOSCIENCES: OVERALL PRODUCT PORTFOLIO

196 NEXT BIOSCIENCES: PRODUCT PORTFOLIO FOR GLOBAL NIPT MARKET

197 NEXT BIOSCIENCES: SWOT ANALYSIS

198 NIPD GENETICS: OVERALL PRODUCT PORTFOLIO

199 NIPD GENETICS: PRODUCT PORTFOLIO FOR GLOBAL NIPT MARKET

200 NIPD GENETICS : SWOT ANALYSIS

201 PERKINELMER, INC.: OVERALL PRODUCT PORTFOLIO

202 PERKINELMER, INC.: PRODUCT PORTFOLIO FOR GLOBAL NIPT MARKET

203 PERKINELMER, INC.: OVERALL FINANCIALS (2015-2017)

204 PERKINELMER, INC.: NET REVENUE BY BUSINESS SEGMENT (2015-2017)

205 PERKINELMER, INC.: NET REVENUE BY REGION (2015-2017)

206 PERKINELMER, INC.: SWOT ANALYSIS

207 PREMAITHA HEALTH PLC: OVERALL PRODUCT PORTFOLIO

208 PREMAITHA HEALTH PLC: PRODUCT PORTFOLIO FOR GLOBAL NIPT MARKET

209 PREMAITHA HEALTH: OVERALL FINANCIALS (2015-2017)

210 PREMAITHA HEALTH: NET REVENUE BY REGION (2015-2017)

211 PREMAITHA HEALTH PLC: SWOT ANALYSIS

212 QUEST DIAGNOSTICS INCORPORATED: OVERALL PRODUCT PORTFOLIO

213 QUEST DIAGNOSTICS INCORPORATED: PRODUCT PORTFOLIO FOR GLOBAL NIPT MARKET

214 QUEST DIAGNOSTICS INCORPORATED: OVERALL FINANCIALS (2015-2017)

215 QUEST DIAGNOSTICS INCORPORATED: NET REVENUE BY BUSINESS SEGMENT (2015-2017)

216 QUEST DIAGNOSTICS INCORPORATED: NET REVENUE BY DIS SEGMENT (2015-2017)

217 QUEST DIAGNOSTICS INCORPORATED: SWOT ANALYSIS

218 LABORATORY CORPORATION OF AMERICA HOLDINGS : OVERALL PRODUCT PORTFOLIO

219 LABORATORY CORPORATION OF AMERICA HOLDINGS: PRODUCT OFFERINGS FOR GLOBAL NIPT MARKET

220 LABORATORY CORPORATION OF AMERICA HOLDINGS: OVERALL FINANCIALS (2015-2017)

221 LABORATORY CORPORATION OF AMERICA HOLDINGS: NET REVENUE BY BUSINESS SEGMENT (2015-2017)

222 LABORATORY CORPORATION OF AMERICA HOLDINGS: NET REVENUE BY REGION (2015-2017)

223 LABORATORY CORPORATION OF AMERICA HOLDINGS: SWOT ANALYSIS

224 GLOBAL NIPT MARKET SEGMENTATION

225 CONSIDERED FACTORS FOR DATA PREDICTION AND MODELING


More Publications